Category survey

RNA dysregulation in neurodegeneration Investments > €500k United States of America Motor neurone diseases 2016    

Prospective study of biomarkers and risk factors for ALS incidence and progressio Investments > €500k United States of America Motor neurone diseases 2016    

Influenza, Inflammation, and Parkinsons Disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Tr Investments > €500k United States of America Spinal muscular atrophy (SMA) 2016    

EXERCISE AND PARKINSONS: COMPARING INTERVENTIONS AND EXPLORING NEURAL MECHANISMS Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Gene-Environment Interactions in Neurodegeneration: Role of Efflux Transporters Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

PGC-1alpha and Pitx3 as individual and combined targets for neuroprotection Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

TDP-43, RNA Metabolism, and ALS/FTD Pathology Investments > €500k United States of America Motor neurone diseases 2016    

Spinal muscular atrophy: inducing SMN expression Investments > €500k United States of America Spinal muscular atrophy (SMA) 2016    

Molecular phenotyping of cortical cell types in multiple rodent models of ALS Investments > €500k United States of America Motor neurone diseases 2016    

An Orally Bioavailable Drug Candidate for Spinal Muscular Atrophy Investments > €500k United States of America Spinal muscular atrophy (SMA) 2016    

Functions of Metabotropic Glutamate Receptor Subtypes Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Neuroprotective Immunity and HIV Dementia Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Lewy body neuropathologies and SNCA gene: variants expression and splicing Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Misfolded ALS-linked Profilin-1: a novel therapeutic target Investments > €500k United States of America Motor neurone diseases 2016    

NAD, PGC-1alpha and SIRT3 as Therapeutics Targets for Huntingtons Disease Investments > €500k United States of America Huntington’s disease 2016    

ALS/FTD mutant C9orf72-induced genetic and nuclear pathology in iPS cell models Investments > €500k United States of America Motor neurone diseases 2016    

Thalamic interactions with the striatum Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Determining how neural activity impairs bioenergetics in PD pathogenesis Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

DBS-Expert: Automated Deep Brain Stimulation Programming Using Functional Mapping Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

PACAP/VIP Glycopeptide Agonists as Neuroprotective Therapies for Parkinsons Disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Huntingtons disease biomarkers and therapeutics Investments > €500k United States of America Huntington’s disease 2016    

Non-invasive Markers of Neurodegeneration in Movement Disorders Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Mechanisms of Huntingtin-induced Neurodegeneration Investments > €500k United States of America Huntington’s disease 2016    

TDP-43 Proteinopathy in ALS-FTD: Mechanism, Target Validation and Biomarker Investments > €500k United States of America Alzheimer’s disease & other dementias|Motor neurone diseases 2016    

Neurodegeneration and Proteotoxicity Dissected in C. elegans and Mammals Investments > €500k United States of America Motor neurone diseases 2016    

Role of C9orf72 in Neurodegeneration Investments > €500k United States of America Motor neurone diseases 2016    

Neurochemical closed-loop controller for smart DBS Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Nanocarriers Designed to Deliver Nucleic Acids to Brain Investments > €500k United States of America Huntington’s disease 2016    

Preventing Experience Dependent Aberrant Plasticity Under Dopamine Deficiency Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Epigenetic Editing of Mutant C9orf72 Investments > €500k United States of America Motor neurone diseases 2016    

Regulation of mitochondrial motility and mitophagy by LRRK2. Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Hexanucleotide repeat translation in ALS and Frontotemporal Dementia Investments > €500k United States of America Alzheimer’s disease & other dementias|Motor neurone diseases 2016    

HTS to identify small molecules to disrupt abnormal huntingtin interactions in HD Investments > €500k United States of America Huntington’s disease 2016    

Role of Parkin in Familial and Idiopathic Parkinsons Disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

RNA decay in amyotrophic lateral sclerosis and frontotemporal lobar degeneration Investments > €500k United States of America Alzheimer’s disease & other dementias|Motor neurone diseases 2016    

LRRK2-mediated molecular and synaptic events in the striatum Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

alpha-Synuclein Inhibition of Mitochondrial Protein Import Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Targeting a SMN lncRNA for the treatment of SMA Investments > €500k United States of America Spinal muscular atrophy (SMA) 2016    

Biological Determinants of Impulsivity in Parkinsons Disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

NINDS NEXT: Childrens Hospital Boston Clinical Research Site Investments > €500k United States of America Spinal muscular atrophy (SMA) 2016    

Cortical-Subcortical Interaction in PD and Normal Speech Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Synergistic Neuroprotective Mechanisms of Coffee Components in Parkinsons Diseas Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Pathological role of c-Abl in alpha-synucleinoapathy Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Molecular mechanisms of huntingtin misfolding Investments > €500k United States of America Huntington’s disease 2016    

Understanding the effects of deep brain stimulation on cortical processing Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Emergence and evolution of social self-management of Parkinsons disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Developing ASO Therapy for Repeat Expanded C9orf72 ALS-FTD Investments > €500k United States of America Motor neurone diseases 2016    

The Gut Microbiome in Parkinson Disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Parkinson Disease: Predicting the Future Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016